The biological variation factors for cholesterol in circulating immune complexes (CIC-cholesterol) were studied in 941 unselected supposedly healthy volunteers, ages 4 to 78 years. We found a complex effect of age, including the existence of two peaks of CIC-cholesterol, one in males between 11 and 14 years and in females between 11 and 30 years, and in both sexes another peak between 41 and 60 years, and in both sexes a decrease between 31 and 40 years. By use of multiple regression analysis and after adjustment for age, CIC-cholesterol was positively related to plasma cholesterol concentration and leukocyte count, values being lower in females than in males and among subjects taking anti-inflammatory drugs. In addition, CIC-cholesterol was measured in 76 coronary angiography patients and in 100 supposedly healthy controls, ages 30 to 77 years. We noticed a significant increase (P 0.05) of CIC-cholesterol when patients were affected by coronary stenosis between 20% and 50% (71.8 ± 52.5 mol/L vs 46.2 ± 45.9 .tmol/L in controls), but this was less pronounced in those with >50% of obstruction (58.9 ± 54.3 mol/L); however, serum total cholesterol was not modified or even surprisingly slightly decreased in the coronary angiography individuals. Nevertheless, an important overlap of values in controls and patients makes questionable the usefulness of this variable in clinical practice.
941 unselected supposedly healthy volunteers, ages 4 to 78 years. We found a complex effect of age, including the existence of two peaks of CIC-cholesterol, one in males between 11 and 14 years and in females between 11 and 30 years, and in both sexes another peak between 41 and 60 years, and in both sexes a decrease between 31 and 40 years. By use of multiple regression analysis and after adjustment for age, CIC-cholesterol was positively related to plasma cholesterol concentration and leukocyte count, values being lower in females than in males and among subjects taking anti-inflammatory drugs. In addition, CIC-cholesterol was measured in 76 coronary angiography patients and in 100 supposedly healthy controls, ages 30 to 77 years. We noticed a significant increase (P 0.05) of CIC-cholesterol when patients were affected by coronary stenosis between 20% and 50% (71.8 ± 52.5 mol/L vs 46.2 ± 45.9 .tmol/L in controls), but this was less pronounced in those with >50% of obstruction (58.9 ± 54.3 mol/L); however, serum total cholesterol was not modified or even surprisingly slightly decreased in the coronary angiography individuals. Nevertheless, an important overlap of values in controls and patients makes questionable the usefulness of this variable in clinical practice. In the clinical study concerning coronary atherosclerosis, the statistical significance of differences between controls and patients was tested with the MannWhitney rank sum test for CIC-cholesterol, or with the t-test for unpaired data for the other analytes.
Results
Apolipoprotein and immunoglobulin content of GIG. CIC isolated from 12 healthy subjects' sera were submitted to SDS-PAGE; the apolipoproteins were detected after immunoblotting with anti-LDL or anti-apo A-I polyclonal antibodies. Typical patterns are shown in Fig. 1. Fig. lB gives evidence that apo A-I is present 
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Arithmetic in CIC (lanes b and c). Similarly, although it appears extensively fragmented, apo B is found in the same CIC (Fig. 1A, lanes b and c) . Besides the native apo B (apo B 100) and many minor fragments, a major fragment (apo B 74) with a molecular mass of 74% of that of the native apolipoprotein is present. In the PEG precipitates we found IgG and 1gM, but were not able to detect any IgA (data not shown).
Effect of PEG 6000 on free lipoproteins.
No significant amounts of cholesterol were precipitated when free VLDL, LDL, or HDL was submitted to a PEG 6000 treatment similar to that applied to fresh sera. 
